Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
 Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
 Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
Date: Wednesday 21st September - Thursday 22nd September 2022
Time:
21st = 12:30-17:00 | 22nd = 09:00-17:00 BST
21st = 13:30-18:00 | 22nd = 10:00-18:00 CEST
Location: Online
Who is this event intended for? Pre-Clinical Statisticians in the Pharmaceutical Industry, with interest and/or some basic knowledge of R/STAN/BUGS and Bayesian statistics.
What is the benefit of attending? This workshop offers the chance to meet with colleagues across industry and learn more about Bayesian Methodology and its applications in pre-clinical.
This is the pre-clinical SIG’s 10th workshop and will be the first one run virtually. Our theme for this workshop is Bayesian; the workshop will run over a day and a half and will include a training course on Bayesian methods (see more below), two presentations on applications of Bayesian methodology in a pre-clinical setting and a breakout session.
Bayesian Statistics for Preclinical Research: New Opportunities
The course will start by introducing the key concepts of Bayesian statistics, emphasizing the context and key objectives of preclinical research in pharmaceutical and medical device development. We then move on to show how Bayesian thinking and practices are a fit-for-purpose paradigm. Over the last decade, preclinical research has been identified in the literature as an area of research suffering from a lack of reproducibility. Causes for this are many, but in this course, we’ll show how to frame a Bayesian strategy to address reproducibility concerns by proposing new study designs, modelling, and decision-making. Preclinical research is a learning process, making Bayesian statistical learning a very natural partnership.
Key topics covered by the course include:
Bruno Boulanger, Senior Director, PharmaLex
Bradley Carlin, Senior Advisor, PharmaLex
Bayesian Tumor volume analysis with BRMS R package
Marie Miossec
In cancer drug development, demonstrated efficacy in tumor xenograft experiments on severe combined immunodeficient mice who are grafted with human tumor tissues or cells is an important step to bring a promising compound to human. A key outcome variable is tumor volumes measured over a period of time, while mice are treated with certain treatment regimens. The tumor growth inhibition delta T/delta C ratio is commonly used to quantify treatment effects in such drug screening tumor xenograft experiments In this presentation, we propose a Bayesian approach to make a statistical inference of the T/C ratio, including both hypothesis testing and a credibility interval estimate. Through a practical case, implementation, diagnosis, model selection and results with the BRMS R package will be discussed.
A Bayesian, Generalized Frailty Model for Comet Assays
Helena Geys
This paper proposes a flexible modelling approach for so-called comet assay data regularly encountered in pre-clinical research. While such data consist of non-Gaussian outcomes in a multi-level hierarchical structure, traditional analyses typically completely or partly ignore this hierarchical nature by summarizing measurements within a cluster. Non-Gaussian outcomes are often modelled using exponential family models. This is true not only for binary and count data, but also for, e.g., time-to-event outcomes. Two important reasons for extending this family are: (1) the possible occurrence of over dispersion, meaning that the variability in the data may not be adequately described by the models which often exhibit a prescribed mean-variance link, and (2) the accommodation of a hierarchical structure in the data, owing to clustering in the data. The first issue is dealt with through so-called over dispersion models. Clustering is often accommodated through the inclusion of random subject-specific effects. Though not always, one conventionally assumes such random effects to be normally distributed. In the case of time-to-event data, one encounters, for example, the gamma frailty model (Duchateau and Janssen 2007). While both of these issues may occur simultaneously, models combining both are uncommon. Molen berghs et al (2010) proposed a broad class of generalized linear models accommodating over dispersion and clustering through two separate sets of random effects. In Ghebretinsae et al, we used this method to model data from a comet assay with a three-level hierarchical structure. Whereas a conjugate gamma random effect is used for the over dispersion random effect, both gamma and Normal random effects are considered for the hierarchical random effect. Apart from model formulation, we place emphasis on Bayesian estimation.
This Workshop is open to both Members and Non-Members of PSI. Please see below for confirmation of fees.
PSI Members = £125+VAT
PSI Non-Members = £125+VAT
Please note: this event will take place online via Zoom, and has a limited number of places available.
To register for this workshop, please click here.
|
Speaker |
Biography |
Bruno Boulanger |
Bruno Boulanger has 25 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in USA. Bruno joined UCB Pharma in 2007 as Director of Exploratory Statistics. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research. |
Brad Carlin |
Brad Carlin is a statistical researcher, methodologist, consultant, and instructor. He currently serves as Senior Advisor for Data Science and Statistics at PharmaLex, an international pharmaceutical consulting firm. Prior to this, he spent 27 years on the faculty of the Division of Biostatistics at the University of Minnesota School of Public Health, serving as division head for 7 of those years. He has also held visiting positions at Carnegie Mellon University, Medical Research Council Biostatistics Unit, Cambridge University (UK), Medtronic Corporation, HealthPartners Research Foundation, the M.D Anderson Cancer Center, and AbbVie Pharmaceuticals. He has published more than 185 papers in refereed books and journals, and has co-authored three popular textbooks: “Bayesian Methods for Data Analysis” with Tom Louis, “Hierarchical Modeling and Analysis for Spatial Data” with Sudipto Banerjee and Alan Gelfand, and "Bayesian Adaptive Methods for Clinical Trials" with Scott Berry, J. Jack Lee, and Peter Muller. From 2006-2009 he served as editor-in-chief of Bayesian Analysis, the official journal of the International Society for Bayesian Analysis (ISBA). During his academic career, he served as primary dissertation adviser for 20 PhD students. Dr. Carlin has extensive experience teaching short courses and tutorials, and won both teaching and mentoring awards from the University of Minnesota. During his spare time, Brad is a health musician and bandleader, providing keyboards, guitar, and vocals in a variety of venues. |
|
|
Marie is a biostatistician engineer at IT&M STATS. She was graduated from ENSAI (National School of Statistics and Information Analysis, France) in 2019 with a master's degree specializing in statistics for life sciences. She has been working for SANOFI as a contractor for three years in the team in charge of biostatistical support to non-clinical efficacy & safety studies. |
|
|
Helena Geys is Global head of the Discovery and Nonclinical Safety Statistics group at Johnson and Johnson. Helena joined J&J 18 years ago during which period she has made significant contributions in various areas of nonclinical statistics: discovery, toxicology, manufacturing. She is an active participant in many professional organizations, and has shown herself a contributor to many successful external and cross-pharma initiatives and academic collaborations leading to impactful successes in drug development strategies. The results of her research have been published in >100 methodological and applied publications on clustered non-normal data, risk assessment, spatial epidemiology, translational medicine and surrogate marker validation. In addition to her assignment at Janssen, Helena has a strong passion for teaching and mentoring. She combines her work at Janssen Pharmaceutica with a position as tenure-track professor in biostatistics at the Data Science Institute of Hasselt University (Belgium) and has mentored and coached >30 master and PhD students. |
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This is an interactive online training workshop providing an in-depth review of the estimand framework as laid out by ICH E9(R1) addendum with inputs from estimand experts, case studies, quizzes and opportunity for discussions. You will develop an estimand in a therapeutic area of interest to your company. In an online break-out room, you will join a series of team discussions to implement the estimand framework in a case study, aligning estimands, design, conduct, analysis, (assumptions + sensitivity analyses) to the clinical objective and therapeutic setting.
Webinar dedicated to the topic of dissolution of oral solid dosage forms; opportunity to hear from statisticians working in the CMC field, with open question and answers. In addition, the CMC Statistical Network Europe special interest group will discuss advocacy opportunities, have your say to contribute to the future direction.
Initially a brief introduction to AI will be given, followed by a presentation of various applications in medicinal product lifecycle. Several aspects will be discussed including performance, theoretical and practical conditions and also regulatory guidelines.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Who is this event intended for? Statisticians with an interest understanding dose-finding in oncology. What is the benefit of attending? Learn about the state of oncology dose finding, particularly in light of current FDA guidance.
The book club’s usual focus is to read and discuss professional development books. In this short format event you can more easily develop you career without the commitment of reading the whole book - simply listen to the 1-hour long podcast before joining the interactive session on 21 May.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
The Institute of Cancer Research are seeking to appoint a Research Group Leader to join The CRUK Clinical Trials and Statistics Unit at the ICR.
The BioMarin internship programme will enable students to gain valuable experience and knowledge of the processes and systems within BioMarin, whilst gaining an insight into the pharmaceutical/biotech industry.
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Amazon Web Services offers a broad set of global cloud-based products including compute, storage, databases, analytics, networking, mobile, developer tools, management tools, IoT, security, and enterprise applications.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Session | |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | 7 days | |
AWS Classic Load Balancer Cookie: Load Balancing Cookie: Used to map the session to the instance. Same value as AWSELB. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
| AWSALBCORS | psi.glueup.com | 7 days | |
Amazon Web Services cookie. This cookie enables us to allocate server traffic to make the user experience as smooth as possible. A so-called load balancer is used to determine which server currently has the best availability. The information generated cannot identify you as an individual. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
